Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Tomko who wrote (527)	1/23/1998 9:15:00 AM
From: E. Graphs	Read Replies (1) of 834

TXB submits more info: biz.yahoo.com >>Texas Biotechnology Corporation (Amex: TXB - news) today announced that FDA review of its new drug application (NDA) for NOVASTAN(R), in the management of patients with heparin-induced thrombocytopenia (HIT), has been extended by the agency for up to 90 days. The FDA has extended the review time in order to consider new data from a follow-on study (ARG-915) in the same patient population as those participating in the pivotal study, ARG-911. Based upon the extension to review additional data, the Company still expects to receive a decision from the FDA within its original time frame of the end of second quarter 1998. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next